TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18373122

Group type: EXPERIMENTAL
Intervention: Effortful saliva swallowing
Number of subjects: 27

Group type: COMPARATOR
Intervention: Noneffortful saliva swallowing
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control task (repetitive apposition of the dominant thumb and index finger)
Number of subjects: 27
Study: 16389981

Group type: EXPERIMENTAL
Intervention: Contrast-enhanced MDCT
Number of subjects: 68
Study: 12472583

Group type: EXPERIMENTAL
Intervention: 2 mg of micronized 17beta‐oestradiol (E2)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 2 mg of micronized 17beta‐oestradiol + 10 mg dydrogesterone (E2 + D)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 9506490

Group type: EXPERIMENTAL
Intervention: Triamcinolone diacetate, 40 mg intramuscular (i.m.)
Number of subjects: 154

Group type: COMPARATOR
Intervention: Prednisone, 40 mg/day orally for 5 days
Number of subjects: 154
Study: 7922010

Group type: EXPERIMENTAL
Intervention: Buffy coat preparation method with yield-enhancing change
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Autologous marrows purged with 4HC
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Allogeneic marrow infusion
Number of subjects: 29
Study: 3049173

Group type: EXPERIMENTAL
Intervention: Topical 2% fenticonazole cream
Number of subjects: 41

Group type: COMPARATOR
Intervention: Topical 1% bifonazole cream
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Overall clinical evaluation
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Statistical significance
Number of subjects: 41
Study: 11288030

Group type: EXPERIMENTAL
Intervention: Naloxone (NAL) infusion (1.6 mg/h for 2.5 hours) during GHRH testing
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: GHRH (1 microg/kg as an IV bolus)
Number of subjects: 10
Study: 30411602

Group type: EXPERIMENTAL
Intervention: Power RMT (gradually increasing resistance)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Endurance RMT (constant resistance)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 13
Study: 30408100

Group type: EXPERIMENTAL
Intervention: Patient reported outcome measures (PROMs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tests of Eustachian tube (ET) opening including tympanometry, sonotubometry, and tubomanometry
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of tests of ET function
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Expert panel diagnosis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Index tests (14 tests of ET opening)
Number of subjects: 0
Study: 27138896

Group type: EXPERIMENTAL
Intervention: Bronchial blocker (BB)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Left double-lumen endotracheal tube (DL-ETT)
Number of subjects: 40
Study: 25001158

Group type: EXPERIMENTAL
Intervention: Intravitreal injection of 0.5 mg bevacizumab
Number of subjects: 13

Group type: COMPARATOR
Intervention: Conventional laser photoablation
Number of subjects: 13
Study: 22469877

Group type: EXPERIMENTAL
Intervention: Mirror therapy program (25 mins, twice a day, five times a week, for 4 weeks)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Mirror therapy program
Number of subjects: 26

Group type: COMPARATOR
Intervention: Standard rehabilitation program (control group)
Number of subjects: 26
Study: 19995097

Group type: EXPERIMENTAL
Intervention: Rivastigmine transdermal patch (9.5 mg/24 h)
Number of subjects: 1195
Study: 17567301

Group type: EXPERIMENTAL
Intervention: Adapalene gel, 0.1% once daily (QD)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Adapalene gel, 0.1% every other day (QoD)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 49
Study: 15692069

Group type: EXPERIMENTAL
Intervention: ABO-compatible platelets, stored for 48 hours or less, large doses of platelets
Number of subjects: 533

Group type: EXPERIMENTAL
Intervention: UV-B or gamma irradiation
Number of subjects: 533

Group type: EXPERIMENTAL
Intervention: Filtered apheresis platelets, increased dose of platelets transfused
Number of subjects: 533

Group type: COMPARATOR
Intervention: Heparin administration, fever, bleeding, increasing number of platelet transfusions, increasing weight, at least 2 pregnancies, male gender
Number of subjects: 533

Group type: COMPARATOR
Intervention: Lymphocytotoxic antibody positivity
Number of subjects: 533

Group type: COMPARATOR
Intervention: None specified
Number of subjects: 533
Study: 12200204

Group type: EXPERIMENTAL
Intervention: Exercise in bright light (group A)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Exercise in normal indoor illumination (group B)
Number of subjects: 80
Study: 10068658

Group type: EXPERIMENTAL
Intervention: CD34-selected peripheral blood progenitor cells
Number of subjects: 131

Group type: COMPARATOR
Intervention: Unselected peripheral blood progenitor cells
Number of subjects: 131
Study: 7751898

Group type: EXPERIMENTAL
Intervention: All-trans retinoic acid (RA) 45 mg/m2 orally twice per day for 14 days (Cycle 1)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: All-trans retinoic acid (RA) 45 mg/m2 orally twice per day for 14 days plus ketoconazole 400 mg orally for one dose, then 200 mg orally three times per day for 14 days (Cycle 2)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Ketoconazole administration
Number of subjects: 13

Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 13
Study: 2185460

Group type: EXPERIMENTAL
Intervention: Active PEMT units
Number of subjects: 20

Group type: COMPARATOR
Intervention: Facsimile placebo units
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Active PEMT units (after 3 weeks)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Facsimile placebo units (after 3 weeks)
Number of subjects: 20
Study: 647198

Group type: EXPERIMENTAL
Intervention: Wound drainage in clean surgical wounds
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Wound drainage in potentially contaminated wounds
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Wound drainage in frankly contaminated wounds
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Presence of drains in contaminated wounds
Number of subjects: 250
Study: 31913961

Group type: EXPERIMENTAL
Intervention: Mild Cognitive Impairment (MCI) diagnosed according to Petersen criteria
Number of subjects: 1960

Group type: EXPERIMENTAL
Intervention: Age increase
Number of subjects: 1960

Group type: EXPERIMENTAL
Intervention: Education increase
Number of subjects: 1960

Group type: EXPERIMENTAL
Intervention: APOE-ε4 carriage
Number of subjects: 1960
Study: 30957508

Group type: EXPERIMENTAL
Intervention: I-STAND intervention
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study: 29029681

Group type: EXPERIMENTAL
Intervention: Standard volitional help sheet (10 critical situations)
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Single situation volitional help sheet (1 generic situation)
Number of subjects: 133

Group type: COMPARATOR
Intervention: Control condition (no implementation intentions)
Number of subjects: 133
Study: 27125966

Group type: EXPERIMENTAL
Intervention: FE75C
Number of subjects: 785

Group type: COMPARATOR
Intervention: FE50C
Number of subjects: 785

Group type: EXPERIMENTAL
Intervention: Hormone Manipulation (HM; tamoxifen or LHRH agonists)
Number of subjects: 785

Group type: EXPERIMENTAL
Intervention: Hormone Manipulation (HM; tamoxifen or LHRH agonists) in ER+/unknown disease
Number of subjects: 785

Group type: EXPERIMENTAL
Intervention: Overall treatment groups (FE50C-HM, FE50C+HM, FE75C-HM, FE75C+HM)
Number of subjects: 785
Study: 23884688

Group type: EXPERIMENTAL
Intervention: Hybrid search with minimized familiarity of targets (Experiment 1)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Encouraged flexible retrieval of target information (Experiment 2)
Number of subjects: 0
Study: 22296781

Group type: EXPERIMENTAL
Intervention: Insulin (daily bedtime subcutaneous NPH insulin)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Usual care (oral hypoglycemic agents)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Insulin
Number of subjects: 78

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 78
Study: 20668324

Group type: EXPERIMENTAL
Intervention: Eicosapentaenoic acid (EPA) 2.4 g/day for 2 years
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control group (no EPA treatment)
Number of subjects: 62
Study: 17619859

Group type: EXPERIMENTAL
Intervention: 40 mg rimonabant daily for 15 days
Number of subjects: 42

Group type: COMPARATOR
Intervention: 90 mg rimonabant on day 15 after 14 days of placebo
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo for 15 days
Number of subjects: 42
Study: 16320974

Group type: EXPERIMENTAL
Intervention: Candesartan (8 to 16mg per day)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Candesartan (8 to 16mg per day) with DASH diet
Number of subjects: 102

Group type: COMPARATOR
Intervention: DASH diet
Number of subjects: 102
Study: 16363278

Group type: EXPERIMENTAL
Intervention: Pulsatility index (PI) assessed at the ankle arteries by colour Doppler ultrasonography
Number of subjects: 106

Group type: COMPARATOR
Intervention: Ankle-brachial Doppler index
Number of subjects: 106

Group type: COMPARATOR
Intervention: Systolic ankle pressure
Number of subjects: 106
Study: 11573666

Group type: EXPERIMENTAL
Intervention: Intrathecal sufentanil 20 microg combined with morphine 200 microg
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Intrathecal sufentanil and morphine
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control group (not specified intervention)
Number of subjects: 15
Study: 9757882

Group type: EXPERIMENTAL
Intervention: Systemic methotrexate therapy
Number of subjects: 80

Group type: COMPARATOR
Intervention: Laparoscopic salpingostomy
Number of subjects: 80
Study: 7841891

Group type: EXPERIMENTAL
Intervention: Group rehabilitation programme (four 3-hour sessions per week)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Group rehabilitation programme
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Experimental group
Number of subjects: 12
Study: 3340423

Group type: EXPERIMENTAL
Intervention: Facilitation of the release of constrained and overcontrolled negative affect
Number of subjects: 18

Group type: COMPARATOR
Intervention: Information about pain and depression
Number of subjects: 18
Study: 29866192

Group type: EXPERIMENTAL
Intervention: Artemether-lumefantrine (AL)
Number of subjects: 680

Group type: COMPARATOR
Intervention: Amodiaquine-artesunate (AQAS)
Number of subjects: 680
Study: 28689102

Group type: EXPERIMENTAL
Intervention: Intravenous methylprednisolone (1 dose of 1 g IV) once a month for 12 months
Number of subjects: 103
Study: 25142619

Group type: EXPERIMENTAL
Intervention: Family-Based Treatment (FBT)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Systemic Family Therapy (alternate form)
Number of subjects: 45
Study: 23973699

Group type: EXPERIMENTAL
Intervention: Zotarolimus-eluting stent (ZES)
Number of subjects: 650

Group type: COMPARATOR
Intervention: Everolimus-eluting stent (EES)
Number of subjects: 650
Study: 21483712

Group type: EXPERIMENTAL
Intervention: Full intervention (evidence‐based guidelines, training, job aides, local facilitation, supervision, and face‐to‐face feedback)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Full intervention
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control intervention (guidelines, didactic training, job aides, and written feedback)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control intervention
Number of subjects: 8
Study: 18582947

Group type: EXPERIMENTAL
Intervention: Vitamin C (ascorbic acid)
Number of subjects: 0
Study: 16817042

Group type: EXPERIMENTAL
Intervention: Phacoemulsification with polyacrylic intraocular lens (IOL) implantation
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 20
Study: 12756354

Group type: COMPARATOR
Intervention: Normal values (healthy subjects)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Older age group (>70 years)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Asian subjects
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: African American subjects
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Legs with venous obstructive disease (with trophic changes)
Number of subjects: 0
Study: 11008917

Group type: EXPERIMENTAL
Intervention: Perceived absolute risk of breast cancer
Number of subjects: 581

Group type: EXPERIMENTAL
Intervention: Perceived comparative risk of breast cancer
Number of subjects: 581
Study: 8943170

Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin (LMWH) 1750 anti-Xa IU daily
Number of subjects: 1351

Group type: COMPARATOR
Intervention: Standard unfractionated heparin (UFH) 5000 IU twice a day
Number of subjects: 1351
Study: 1586105

Group type: EXPERIMENTAL
Intervention: Nal‐Glu (GnRH antagonist) for 6 weeks
Number of subjects: 15

Group type: COMPARATOR
Intervention: Nal‐Glu plus testosterone enanthate (100 mg/wk)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo injections
Number of subjects: 15
Study: 4026044

Group type: EXPERIMENTAL
Intervention: Almitrine 50 mg orally twice a day for 14 days
Number of subjects: 9
Study: 31783900

Group type: EXPERIMENTAL
Intervention: STAR program (Sepsis Transition and Recovery program)
Number of subjects: 708

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 708
Study: 28760512

Group type: EXPERIMENTAL
Intervention: Caregiver-rated EQ-VAS scores <50
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: Caregiver-rated EQ-VAS scores between 50 and 64
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: Caregiver-rated EQ-VAS scores between 65 and 79
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: Self-rated EQ-VAS
Number of subjects: 330
Study: 26595549

Group type: EXPERIMENTAL
Intervention: SRT2104 50 mg daily
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: SRT2104 500 mg daily
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: SRT2104 (both doses)
Number of subjects: 26
Study: 24134594

Group type: EXPERIMENTAL
Intervention: Client motivational language (arguments for and against change) during CBT sessions.
Number of subjects: 0
Study: 21898014

Group type: EXPERIMENTAL
Intervention: Combined thoracoscopic-laparoscopic esophagectomy (TLE)
Number of subjects: 185

Group type: COMPARATOR
Intervention: Thoracoscopic esophagectomy (TE)
Number of subjects: 185

Group type: COMPARATOR
Intervention: Open esophagectomy (OE)
Number of subjects: 185
Study: 20368196

Group type: EXPERIMENTAL
Intervention: Intensified glucose control based on insulin (I-group)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Ongoing glucose-lowering treatment (C-group)
Number of subjects: 93
Study: 17990195

Group type: EXPERIMENTAL
Intervention: SHR-5 extract (340 mg/day)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: SHR-5 extract (680 mg/day)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 89
Study: 16167227

Group type: EXPERIMENTAL
Intervention: Gastrointestinal decompression after operation
Number of subjects: 368

Group type: COMPARATOR
Intervention: No gastrointestinal decompression after operation
Number of subjects: 368
Study: 12740266

Group type: EXPERIMENTAL
Intervention: IV tobramycin and ceftazidime
Number of subjects: 262
Study: 10036845

Group type: EXPERIMENTAL
Intervention: Tobacco cessation services (TCS) offered by dental offices
Number of subjects: 3088

Group type: EXPERIMENTAL
Intervention: Interest in quitting tobacco
Number of subjects: 3088

Group type: COMPARATOR
Intervention: Dentists' perception of patient expectations for TCS
Number of subjects: 3088

Group type: COMPARATOR
Intervention: Barriers to providing TCS as reported by dentists
Number of subjects: 3088
Study: 7793595

Group type: EXPERIMENTAL
Intervention: Homemade force pressure transducer
Number of subjects: 20

Group type: COMPARATOR
Intervention: Commercially available accelerometer
Number of subjects: 20
Study: 1922220

Group type: EXPERIMENTAL
Intervention: 30 mg of aspirin
Number of subjects: 3131

Group type: COMPARATOR
Intervention: 283 mg of aspirin
Number of subjects: 3131
Study: 7349618

Group type: EXPERIMENTAL
Intervention: Naloxone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 6420959

Group type: EXPERIMENTAL
Intervention: Ibuprofen (instead of steroids) with azathioprine and ATGAM for three months
Number of subjects: 33

Group type: COMPARATOR
Intervention: Azathioprine, high doses of prednisolone, and ATGAM for three months
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Experimental group (Ibuprofen)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control group (steroids)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 33
Study: 31006972

Group type: EXPERIMENTAL
Intervention: Phonophoresis of piroxicam (PH-P)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Phonophoresis of dexamethasone sodium phosphate (PH-Dex)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Nondrug ultrasound (US) therapy
Number of subjects: 33
Study: 28673117

Group type: EXPERIMENTAL
Intervention: Social robot intervention for teaching gesture recognition and production
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Social robot intervention for teaching gesture recognition
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Social robot intervention for teaching gesture production
Number of subjects: 13

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 13
Study: 27043932

Group type: EXPERIMENTAL
Intervention: β‐glucan
Number of subjects: 69

Group type: COMPARATOR
Intervention: Control (no β‐glucan)
Number of subjects: 69
Study: 25480588

Group type: EXPERIMENTAL
Intervention: Warfarin plus 75‐100 mg aspirin
Number of subjects: 1016

Group type: COMPARATOR
Intervention: Warfarin only
Number of subjects: 1016
Study: 21771042

Group type: EXPERIMENTAL
Intervention: Relaxation training programme (listening to a 13-minute relaxation programme daily)
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Relaxation training programme
Number of subjects: 129

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 129
Study: 20464781

Group type: EXPERIMENTAL
Intervention: Moderate hypothermia (HYPO group; esophageal temperature 32-33 degrees C) for 24 hours
Number of subjects: 16

Group type: COMPARATOR
Intervention: Normothermia (NORMO group; 36.5-37.5 degrees C) for 24 hours
Number of subjects: 16
Study: 18185146

Group type: EXPERIMENTAL
Intervention: Lutein administration
Number of subjects: 39

Group type: COMPARATOR
Intervention: Cystoid macular edema (CME) presence
Number of subjects: 39

Group type: COMPARATOR
Intervention: Visual acuity (VA) assessment
Number of subjects: 39

Group type: COMPARATOR
Intervention: Retinal thickness measurement
Number of subjects: 39
Study: 15865225

Group type: EXPERIMENTAL
Intervention: PEG-IFN 1.5 microg/kg/week plus RBV 400 mg twice daily (arm A)
Number of subjects: 135

Group type: COMPARATOR
Intervention: PEG-IFN 1.5 microg/kg/week (arm B)
Number of subjects: 135
Study: 11529975

Group type: EXPERIMENTAL
Intervention: Emotion-oriented care
Number of subjects: 0
Study: 9634050

Group type: EXPERIMENTAL
Intervention: Selenium treatment (200 microg daily)
Number of subjects: 974

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 974
Study: 8141220

Group type: EXPERIMENTAL
Intervention: Frequent breast-feeding (nursed 9 times per day)
Number of subjects: 275

Group type: COMPARATOR
Intervention: Demand breast-feeding (nursed 6.5 times per day)
Number of subjects: 275
Study: 3255915

Group type: EXPERIMENTAL
Intervention: Chlortenoxicam
Number of subjects: 0
Study: 30268133

Group type: EXPERIMENTAL
Intervention: Selective decontamination of the digestive tract (SDD)
Number of subjects: 996

Group type: COMPARATOR
Intervention: Selective oropharyngeal decontamination (SOD)
Number of subjects: 996
Study: 26581111

Group type: COMPARATOR
Intervention: E6005 ointment (0.01% to 0.2%) in Study 001
Number of subjects: 76

Group type: COMPARATOR
Intervention: E6005 ointment (0.01% to 0.2%) in Study 101
Number of subjects: 76

Group type: COMPARATOR
Intervention: E6005 ointment (0.01% to 0.2%) in both studies
Number of subjects: 76
Study: 25332324

Group type: EXPERIMENTAL
Intervention: Daily snack made from green leafy vegetables, fruit, and milk (treatment group)
Number of subjects: 1962

Group type: COMPARATOR
Intervention: Low-micronutrient vegetables (potato and onion) (control group)
Number of subjects: 1962
Study: 22954865

Group type: EXPERIMENTAL
Intervention: Virtual Representations of the Self (VRS)
Number of subjects: 0
Study: 19558381

Group type: EXPERIMENTAL
Intervention: Prevent Injury Enhance Performance (PEP) program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (CON) group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Both groups (PEP and CON)
Number of subjects: 0
Study: 17660154

Group type: EXPERIMENTAL
Intervention: 1.25 mg albuterol
Number of subjects: 349

Group type: EXPERIMENTAL
Intervention: 0.62 mg albuterol
Number of subjects: 349

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 349
Study: 15855335

Group type: EXPERIMENTAL
Intervention: Trientine (Cu(II)‐selective chelator)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 0
Study: 11865828

Group type: EXPERIMENTAL
Intervention: Pentoxifylline (PXF)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study: 9498539

Group type: EXPERIMENTAL
Intervention: Thrombolytic regimens
Number of subjects: 247

Group type: EXPERIMENTAL
Intervention: Baseline clinical predictors
Number of subjects: 247

Group type: EXPERIMENTAL
Intervention: Combined model predictors
Number of subjects: 247
Study: 9098301

Group type: EXPERIMENTAL
Intervention: Single intraoperative application of 0.2 mg/ml mitomycin C for 3 minutes
Number of subjects: 227

Group type: EXPERIMENTAL
Intervention: Single intraoperative application of 0.4 mg/ml mitomycin C for 3 minutes
Number of subjects: 227

Group type: EXPERIMENTAL
Intervention: Mitomycin C eye drops 0.2 mg/ml three times daily for 7 days
Number of subjects: 227

Group type: EXPERIMENTAL
Intervention: Mitomycin C eye drops 0.4 mg/ml three times daily for 14 days
Number of subjects: 227

Group type: COMPARATOR
Intervention: Surgery alone (control group)
Number of subjects: 227
Study: 2713212

Group type: EXPERIMENTAL
Intervention: Adenosine infusion at 0.07 mg kg‐1 min‐1
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Adenosine infusion at 0.03 mg kg‐1 min‐1
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Adenosine infusion at 0.005 mg kg‐1 min‐1
Number of subjects: 8